Closed-Loop Insulin Delivery During Pregnancy (IADIABENCEINTE)
Condition: Type 1 Diabetes
MeSH terms: Diabetes Mellitus, Type 1
Study type: Observational

Summary: 
      The imbalance of diabetes is associated with an increased risk of maternal and fetal
      complications. In women, it can cause abortion, hypertension, preeclampsia, and obstructed
      labor; in the fetus, it increases the risk of many malformations, including neurological and
      cardiac, fetal death in utero, intrauterine growth retardation, macrosomia, prematurity and
      metabolic complications.

      Despite the various therapeutic tools available and used during pregnancy, maintaining blood
      sugar levels within this narrow range remains a challenge.

      Automated Insulin Therapy (IA) Could Further Improve Outcomes With Continuous Glucose
      Monitoring and Increase Percentage of Time Spent on Target Between 63 and 140 mg/dL The
      objective of this observational study is to describe the clinical characteristics, metabolic
      data on MCG and maternal and/or fetal complications in women with T1D treated during
      pregnancy with an AI system available in France.
    

Detailed description: 
      Diabetes imbalance is associated with an increased risk of maternal and fetal complications,
      and achieving target blood glucose levels before and during pregnancy in women with type 1
      diabetes (T1DM) significantly reduces these complications. In women, it can cause abortion,
      hypertension, pre-eclampsia, and dystocic deliveries; in the fetus, it increases the risk of
      numerous malformations, including neurological and cardiac, fetal death in utero,
      intrauterine growth retardation, macrosomia, prematurity, and metabolic complications at
      birth such as neonatal hypoglycemia and hypocalcemia.

      The recommended glycemic targets during pregnancy are strict: HbA1c < 6.5% and time in target
      (between 63 and 140 mg/dL) > 70% (6).

      Despite the various therapeutic tools available and used during pregnancy, maintaining blood
      glucose within this narrow range remains a challenge.

      Automated insulin therapy (AI) could improve further on the results obtained with continuous
      glucose monitoring and increase the percentage of time spent in target between 63 and 140
      mg/dL The objective of this present observational study is to describe the clinical
      characteristics, metabolic data on MCG and maternal and/or fetal complications in women with
      T1DM treated during pregnancy with an AI system available in France, whether this system is
      used before the beginning of the pregnancy or during it.
    

Intervention name(s): Hybrid closed loop insulin delivery systems
Intervention type(s): Device
Intervention description(s): Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
Intervention MeSH terms: Insulin
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Patients followed in the diabetology department of the Centre Hospitalier Sud-Francilien
      
Keywords: artificial pancreas; closed loop insulin delivery; glucose control; pregnancy; type 1 diabetes; observational study